Compare RMBI & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | NKTX |
|---|---|---|
| Founded | 1887 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.9M | 132.8M |
| IPO Year | 2019 | 2020 |
| Metric | RMBI | NKTX |
|---|---|---|
| Price | $13.94 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 16.4K | ★ 728.8K |
| Earning Date | 01-23-2026 | 11-10-2025 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ 21.88 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $44,970,551.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.09 | ★ N/A |
| Revenue Growth | ★ 6.42 | N/A |
| 52 Week Low | $11.37 | $1.31 |
| 52 Week High | $15.24 | $2.74 |
| Indicator | RMBI | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 61.29 |
| Support Level | $13.86 | $1.79 |
| Resistance Level | $14.19 | $2.19 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 56.66 | 67.06 |
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.